IP Library Granted Patent US 12,102,715
Granted Patent B1
US 12,102,715 · App. 17/532,795 · Granted Oct 1, 2024

ROS-responsive liposomes for specific targeting

Inventors: Kimberly Kam (Orinda, CA); Zhan Wang (San Jose, CA); Stephen Morton (Mountain View, CA); Nicole Peck (Redwood City, CA)
Assignee: VERILY LIFE SCIENCES LLC
A61K9/1271A61K9/1277A61K31/7088A61K38/02A61K39/395A61K47/42A61K47/6913A61K49/0032A61K49/0086A61P39/06B01J13/22Y10S977/773Y10S977/906Y10S977/907
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,102,715
App. No.
17/532,795
Granted
Oct 1, 2024
Kind
B1
Abstract

Provided herein are encapsulated liposomes comprising a lipid bilayer, a first polyethylene glycol (PEG) corona, a targeting molecule and a second PEG corona. The second, encapsulating PEG corona can be reversibly linked to the first PEG corona. Also provided are pharmaceutical compositions comprising the encapsulated liposomes and methods of treating a subject with a disease characterized by production of reactive oxygen species (ROS) with the compositions. Also provided are methods of making the encapsulated liposomes disclosed herein.

Claims (10)

1. A method of treating a subject, the method comprising:

administering to the subject a pharmaceutical composition, wherein the subject has cancer characterized by production of reactive oxygen species and wherein the pharmaceutical composition comprises:

an encapsulated liposome comprising:

a lipid bilayer with a first polyethylene glycol (PEG) corona, wherein the first PEG corona further comprises a targeting molecule,

a second PEG corona reversibly linked to the first PEG corona, wherein the reversible links comprise a boronic ester bond, and

one or more active agents, wherein at least one of the one or more active agents is a chemotherapeutic agent; and

a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the includes neoplasms or tumors, lymphoma, or leukemia characterized by the production of ROS.

3. The method of claim 1 , wherein the boronic ester bond is formed from a linker comprising an aryl boronic acid, a phenylboronate, a pyridylboronate, or a cyclohexylboronate.

4. The method of claim 1 , wherein the boronic ester bond is formed from a linker selected from the group consisting of 4-bromomethylphenyl boronic acid pinacol ester, 3-(N,N-dimethylamino)phenyl boronic acid, 2,4-dichlorophenylboronic acid, 4-aminocarbonylphenylboronic acid, 3-chlorophenylboronic acid, 4-hydroxyphenylboronic acid, 4-propylphenylboronic acid, 3-[(E)-2-nitrovinyl)phenylboronic acid, 4-chlorocarbonylphenylboronic anhydride, cyclopenten-1-ylboronic acid, 2-bromopyridine-3-boronic acid, 2,4-ditert-butoxypyrimidin-5-ylboronic acid, 2,4-bis(benzyloxy)pyrimidine-5-boronic acid, 5-phenyl-2-thienylboronic acid, and 5-formylthiophene-3-boronic acid.

Assignments (2)
CHANGE OF ADDRESS Recorded Nov 19, 2024
From: VERILY LIFE SCIENCES LLC
To: VERILY LIFE SCIENCES LLC
Reel/Frame 069390/0656 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2022
From: KAM, KIMBERLY; WANG, ZHAN; MORTON, STEPHEN; PECK, NICOLE
To: VERILY LIFE SCIENCES LLC
Reel/Frame 059562/0988 →
Continuity (3)
Division 16690599 · Nov 21, 2019
Division 15672591 · Aug 9, 2017
Provisional Application 62372990 · Aug 10, 2016